# iSpecimen (ISPC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ISPC
## Company Profile
- Ticker: ISPC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 1.54 USD
- Market cap: 4412071.99 USD
- Last updated: 2026-09-03
## Business Overview
iSpecimen is a healthcare data and biospecimen marketplace company that connects researchers with human biospecimens and related services. Its role is to support research and translational work rather than develop therapies.
## Why The Stock Is Moving

As of Sep 3, 2026, ISPC closed up 3.36% at $1.54. No new same-company headline was identified in the current news window.

## Geographic Base

iSpecimen is headquartered in the United States and listed on NASDAQ. It sits in biotech infrastructure and research services.

## Business Model

The business depends on research demand, platform adoption, and the ability to connect buyers and sample providers efficiently. Investors track revenue growth, customer acquisition, and the health of research spending.

## Landscape Position

iSpecimen belongs in the infrastructure layer of the biotech ecosystem. It is not a drug developer, but it helps enable translational research and discovery.

## Future Catalysts

- iSpecimen’s catalysts are biospecimen marketplace growth and research-customer adoption. The business improves when the platform becomes more embedded in sourcing workflows.

## Recent News
- 2025-01-16 16:01 EST — [iSpecimen Secures Suppliers for COVID-style hMPV Outbreak](https://biopharmsignal.com/news/ISPC/ispecimen-secures-suppliers-for-covid-style-hmpv-outbreak) — Source: iSpecimen
- 2024-12-20 08:30 EST — [iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens](https://biopharmsignal.com/news/ISPC/ispecimen-will-serve-as-a-preferred-provider-of-cancer-biospecimens) — Source: iSpecimen
- 2024-12-13 07:30 EST — [iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers](https://biopharmsignal.com/news/ISPC/ispecimen-reports-positive-results-on-next-day-quote-program-for-researchers-and-providers) — Source: iSpecimen
- 2024-12-12 17:11 EST — [iSpecimen Appoints Robert Lim as CEO and Director](https://biopharmsignal.com/news/ISPC/ispecimen-appoints-robert-lim-as-ceo-and-director) — Source: iSpecimen
- 2024-11-08 07:30 EST — [iSpecimen Named Top Competitor in $4.4 Billion USD Market](https://biopharmsignal.com/news/ISPC/ispecimen-named-top-competitor-in-4-4-billion-usd-market) — Source: iSpecimen